drugset / Trial / NCT05896683

A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants

NCT05896683

Phase 1 Completed 72 enrolled Janssen Research & Development, LLC
RandomizedSequentialOpen-labelBasic science

Summary

The purpose of this study is to assess the extent of availability of drug to the body of four different lazertinib tablet formulations at a single oral dose under fasted conditions in healthy adult participants.

Timeline

Start
2023-05-30
Primary completion
2023-09-01
Completion
2023-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lazertinib Small molecule Oral

Indications

No indication recorded.